Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Has EU Insulin Aspart Biosimilar Approval

Firm Comments on Pricing And Launch Plans For Rival To NovoRapid

Executive Summary

Sanofi has received formal approval from the European Commission for its insulin aspart biosimilar.

You may also be interested in...



Sanofi Labels Biosimilars 'Enormous Distraction'

While in possession of a token biosimilar portfolio and pipeline, Sanofi has made it clear that its R&D dollars are unlikely to be spent on biosimilars, six months after reshaping its pipeline by exiting diabetes and cardiovascular diseases research.

Sanofi’s Insulin Aspart Biosimilar Gets European Nod

Sanofi has received a positive opinion from the CHMP for its insulin aspart biosimilar rival to NovoRapid. Meanwhile, Accord and Janssen-Cilag have also received positive opinions for generics and hybrid medicines.

Sanofi Is First To File Biosimilar Insulin Aspart

The European Medicines Agency is evaluating Sanofi's SAR341402, the first biosimilar insulin aspart product to be submitted for EU marketing authorization. If approved, the product will compete with Novo Nordisk's diabetes drug Novorapid/NovoLog.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133377

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel